NEW YORK (GenomeWeb News) – CombiMatrix today priced its public offering of 12,000 units of preferred of Series D convertible preferred stock and warrants at a price of $1,000 per unit.

Gross proceeds from the offering are $12 million, with net proceeds anticipated to be $10.8 million. The array-based molecular diagnostics developer said that it expects to close the offering on or around Dec. 20.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.